Table 2.
Base-case results for selected HIV re-testing frequencies
| Selected HIV re-testing frequencies | ||||||||
|---|---|---|---|---|---|---|---|---|
| 3 mo | 1 yr | 2 yrs | 3 yrs | 5 yrs | 7.5 yrs |
10 yrs |
30 yrs |
|
| 0.8% incidence | ||||||||
| HCT cost per case identified ($) | 2792 | 696 | 347 | 231 | 139 | 95 | 73 | 36 |
| Total cost ($) per person | 898 | 507 | 435 | 405 | 366 | 322 | 279 | 59 |
| Percent cost from HCT (%) | 56.8 | 24.7 | 14.1 | 9.9 | 6.3 | 4.5 | 3.7 | 3.1 |
| QALYs gained per person | 0.41 | 0.41 | 0.40 | 0.39 | 0.36 | 0.32 | 0.28 | 0.05 |
| CE ratio ($/QALY) | 2196 | 1251 | 1096 | 1045 | 1008 | 998 | 999 | 1198 |
| Reduction in transmission of HIV (%) | 29.8 | 26.8 | 24.8 | 23.5 | 21.5 | 18.9 | 16.4 | 4.9 |
| CE ratio ($/QALY), accounting for infections averted | 1565 | 866 | 760 | 726 | 704 | 701 | 704 | 716 |
| ICER (d$/dQALY), accounting for infections averted | 51604 | 4324 | 1938 | 1166 | 779 | 701 | # | # |
| 1.3% incidence | ||||||||
| HCT cost per case identified ($) | 1734 | 433 | 217 | 145 | 87 | 60 | 46 | 22 |
| Total cost ($) per person | 1079 | 707 | 635 | 601 | 551 | 488 | 423 | 85 |
| Percent cost from HCT (%) | 44.6 | 16.7 | 9.2 | 6.3 | 4.0 | 2.9 | 2.3 | 2.0 |
| QALYs gained per person | 0.63 | 0.63 | 0.61 | 0.60 | 0.56 | 0.50 | 0.43 | 0.07 |
| CE ratio ($/QALY) | 1703 | 1127 | 1033 | 1002 | 981 | 978 | 982 | 1181 |
| Reduction in transmission of HIV (%) | 29.6 | 26.7 | 24.7 | 23.4 | 21.4 | 18.7 | 16.2 | 4.6 |
| CE ratio ($/QALY), accounting for infections averted | 1180 | 765 | 707 | 690 | 681 | 684 | 689 | 703 |
| ICER (d$/dQALY), accounting for infections averted | 30942 | 2650 | 1312 | 886 | 681 | # | # | # |
| 4.0% incidence | ||||||||
| HCT cost per case identified ($) | 589 | 149 | 75 | 51 | 31 | 22 | 17 | 8 |
| Total cost ($) per person | 1787 | 1497 | 1425 | 1376 | 1281 | 1138 | 981 | 144 |
| Percent cost from HCT (%) | 20.3 | 6.0 | 3.2 | 2.2 | 1.4 | 1.0 | 0.8 | 0.7 |
| QALYs gained per person | 1.54 | 1.52 | 1.49 | 1.45 | 1.36 | 1.20 | 1.03 | 0.12 |
| CE ratio ($/QALY) | 1163 | 984 | 956 | 947 | 942 | 947 | 955 | 1157 |
| Reduction in transmission of HIV (%) | 29.1 | 26.1 | 24.1 | 22.8 | 20.8 | 18.0 | 15.4 | 3.3 |
| CE ratio ($/QALY), accounting for infections averted | 749 | 641 | 635 | 636 | 640 | 651 | 660 | 671 |
| ICER (d$/dQALY), accounting for infections averted | 8781 | 833 | 635 | # | # | # | # | # |
QALY = quality-adjusted life-year
# = dominated testing strategy
All cost and benefits have been discounted at a rate of 3% per year. ICER are compared with the next most frequent testing interval, some of which are not shown in the table. (Testing every 6 months, 4 years, 6 years, and 15 years are not shown).